Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2014
Context: The Company filed a Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange containing financial results for the quarter ended June 30, 2014, and a full-year forecast for 2014. This 8-K serves as Regulation FD disclosure of that information.
Key Financial Metrics
Historical Results (Quarter ended June 30, 2014): The filing references the Company's Form 10-Q for this period but does not explicitly state the specific revenue, profit, or cash flow figures within this text. It notes that supplementary financial statements denominated in Japanese yen were disclosed in the Tanshin using an exchange rate of 102.85 JPY/USD as of July 31, 2014.
Full Year 2014 Forecast:
- Revenues: $0 (No revenue expected)
- Operating Loss: $9,094,000
- Net Loss: $9,094,000
- Expected Loss Per Share (Basic and Diluted): $0.38
- Weighted Average Shares: 24,090,000
Material Changes and Comparisons
The filing does not provide specific numerical comparisons to the prior comparable period (e.g., Q2 2013 or Q2 2014 actuals) within the text provided. It states that the Tanshin is substantially the same as the Form 10-Q except for the inclusion of the full-year forecast and supplementary yen-denominated statements.
Guidance, Outlook, and Risks
Management Commentary: The forecast is based on management's assumptions regarding current conditions and trends. Management believes these assumptions are reasonable but cannot assure that business development will align with estimates.
Risks and Uncertainties:
- Actual results may differ materially from estimates due to factors beyond the Company's control.
- Independent auditors have not compiled or reviewed the forecasted results and assume no responsibility for their accuracy.
- Forward-looking statements involve risks regarding regulatory approval, clinical trial progress, product efficacy, patent protection, market competition, and the ability to raise capital.
Investor Verification Checklist
- Verify the specific Q2 2014 financial results (revenue, expenses, cash position) in the referenced Form 10-Q, as they are not detailed in this 8-K.
- Confirm the weighted average share count of 24,090,000 used for the EPS calculation.
- Review the Form 10-K for the year ended December 31, 2013, for detailed risk factors mentioned in the disclosure.
- Monitor the Company's ability to raise capital, given the projected full-year net loss of approximately $9.1 million and zero expected revenue.